Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Ran Reshef, MD, James K. Mangan, MDPhD, Selina M. Luger, MD, Alison Wakoff Loren, MDMS, Elizabeth O. Hexner, MD, Noelle V. Frey, MDMS, Edward A. Stadtmauer, MD, Robin E. Blauser, BSN RN, Lee P. Richman, BA, Austin P. Huffman, BA, Alex Ganetsky, PharmD, Edward P. Acosta, PharmD, James A. Hoxie, MD, Rosemarie Mick, MS, Robert H. Vonderheide, MDDPhil, David L. Porter, MD

Blood (2014) 124 (21): 2491.

https://doi.org/10.1182/blood.V124.21.2491.2491

Published: 2014

Journal Articles

Autologous Stem Cell Transplantation without Hematopoietic Support for the Treatment of Hematological Malignancies in 125 Jehovah’s Witnesses

Shakira Jeanene Grant, MBBS, Patricia Ford, MD, Rosemarie Mick, MS, Gina Keck, RN

Blood (2014) 124 (21): 3976.

https://doi.org/10.1182/blood.V124.21.3976.3976

Published: 2014

Journal Articles

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Sarah J. Nagle, MD, Kaitlin Woo, Rosemarie Mick, MS, Stephen J. Schuster, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jakub Svoboda, MD

Blood (2012) 120 (21): 2689.

https://doi.org/10.1182/blood.V120.21.2689.2689

Published: 2012

Journal Articles

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Blood (2012) 120 (21): 143.

https://doi.org/10.1182/blood.V120.21.143.143

Published: 2012

Journal Articles

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During Trials Combining Sirolimus and Intensive Chemotherapy: Target Inhibition Enhances Response

Margaret Kasner, MD, Selina M. Luger, MD, Grace R Jeschke, Rosemarie Mick, MS, Martin Carroll, MD, Alexander E Perl, MD

Blood (2011) 118 (21): 230.

https://doi.org/10.1182/blood.V118.21.230.230

Published: 2011

Journal Articles

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Ran Reshef, MD, Selina M. Luger, MD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Sunita D. Nasta, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, James A. Hoxie, MD, Stephen G. Emerson, MD, PhD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2011) 118 (21): 1011.

https://doi.org/10.1182/blood.V118.21.1011.1011

Published: 2011

Journal Articles

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Ran Reshef, MD, Rosemarie Mick, MS, Pavel Vassilev, BS, Jacqueline Smith, CRNP, Elizabeth Hexner, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Edward A. Stadtmauer, MD, Selina M. Luger, MD, David L. Porter, MD

Blood (2011) 118 (21): 1939.

https://doi.org/10.1182/blood.V118.21.1939.1939

Published: 2011

Journal Articles

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Ran Reshef, MD, Selina M. Luger, MD, Alison W. Loren, MD, Noelle V. Frey, MD, Steven C. Goldstein, MD, Elizabeth O. Hexner, MD, Edward A. Stadtmauer, MD, Jacqueline Smith, CRNP, Rosemarie Mick, MS, Daniel F. Heitjan, PhD, Susan E. Shetzline, PhD, Gwenn-ael H. Danet-Desnoyers, PhD, Stephen G. Emerson, MD, PhD, James A. Hoxie, MD, Robert H. Vonderheide, MD, PhD, David L. Porter, MD

Blood (2010) 116 (21): 673.

https://doi.org/10.1182/blood.V116.21.673.673

Published: 2010

NARROW

Extended CCR5 Blockade in Graft-Versus-Host Disease Prophylaxis – a Phase II Study

Autologous Stem Cell Transplantation without Hematopoietic Support for the Treatment of Hematological Malignancies in 125 Jehovah’s Witnesses

Outcomes of Patients with Refractory/Relapsed Diffuse Large B-Cell Lymphoma Who Progress After Autologous Stem Cell Transplantation in the Rituximab Era.

Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway

Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During Trials Combining Sirolimus and Intensive Chemotherapy: Target Inhibition Enhances Response

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

Whole Blood Donor Chimerism At Day 30 After Reduced Intensity Conditioned Allogeneic Stem-Cell Transplantation Predicts Disease Relapse, and Is Strongly Associated with Pretransplant Lymphodepletion

Prevention of Graft-Versus-Host Disease by Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only